Grace Therapeutics, Inc. - Asset Resilience Ratio
Grace Therapeutics, Inc. (GRCE) has an Asset Resilience Ratio of 0.02% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Grace Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See GRCE free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Grace Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GRCE market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.00K | 0.02% |
| Total Liquid Assets | $15.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Grace Therapeutics, Inc. maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grace Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Grace Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Grace Therapeutics, Inc. (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Grace Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 0.00% | $0.00 | $73.30 Million | -- |
| 2023-03-31 | 0.02% | $15.00K | $79.12 Million | -10.34pp |
| 2022-03-31 | 10.36% | $13.32 Million | $128.62 Million | -5.32pp |
| 2021-03-31 | 15.67% | $9.79 Million | $62.46 Million | -8.42pp |
| 2019-03-31 | 24.09% | $8.89 Million | $36.90 Million | -2.01pp |
| 2016-03-31 | 26.10% | $5.49 Million | $21.04 Million | -19.78pp |
| 2015-03-31 | 45.88% | $13.64 Million | $29.74 Million | -4.58pp |
| 2014-03-31 | 50.46% | $20.69 Million | $41.01 Million | +20.98pp |
| 2013-03-31 | 29.48% | $3.50 Million | $11.89 Million | -5.76pp |
| 2012-03-31 | 35.24% | $5.57 Million | $15.82 Million | +12.09pp |
| 2011-03-31 | 23.15% | $2.56 Million | $11.07 Million | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more